Open AccessTHE EVALUATION OF RISK FACTORS OF CARDIO-VASCULAR DISEASES IN PATIENTS WITH DIABETES MELLITUS TYPE II DEPENDING ON DEGREE OF COMPENSATION OF CARBOHYDRATE METABOLISM AND IN TREATMENT DYNAMICS
Author(s) -
R. I. Stryuk,
Стрюк Раиса Ивановна,
M.I. Sviridova,
Свиридова М. И,
А А Голикова,
Голикова А. А,
Е. Г. Лобанова,
Лобанова Е. Г
Publication year - 2018
Publication title -
rossijskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9100
pISSN - 0869-2106
DOI - 10.18821/0869-2106-2018-24-1-13-18
Subject(s) - medicine , waist , diabetes mellitus , body mass index , carbohydrate metabolism , endocrinology , hemoglobin , type 2 diabetes mellitus , lipid metabolism , blood sugar , circumference , carbohydrate , gastroenterology , physiology , geometry , mathematics
The study was carried out using sampling of 74 patients (20 males and 54 females) aged from 48 to 75 years (average age 61.5±7.4 years) with diabetes mellitus type II. The analysis was applied to anthropometric parameters, lipid metabolism condition, level of highly sensitive C-reactive protein, tumor necrosis factor-α depending on degree of compensation of carbohydrate metabolism-level of glycosylated hemoglobin (HbA1c). In patients with diabetes mellitus type II with worse compensation of carbohydrate metabolism (HbA1c>7,5%) their body mass, waist circumference, body mass index occurred higher than in patients with HbA1c≤7,5%. The level of highly sensitive C-reactive protein corresponding to risk of development of cardio-vascular diseases was established in 97% of patients and increased level of tumor necrosis factor-α was established in 66% of patients independently of indices of glycemia. The patients were divided in 2 groups. The group I included 50 patients whose treatment was supplemented with mimetic of glucagon-like peptide Exenatid in the mode of double subcutaneous injections in dosage of 5 mkg 2 t per day during a month and then 10 mkg 2t per day during 5 months. The control group included 20 patients receiving a standard sugar-decreasing therapy. The initially analyzed indices had no statistically reliable differences in both groups. In patients of both groups a reliable decreasing of HbA1c was established in 6 months. Only in patients of group I statistically reliable amelioration of lipid specter, decreasing of body mass, waist circumference and level of markers of non-specific inflammation: highly sensitive C-reactive protein and tumor necrosis factor-α.